ModifiedUnitedHealthcarePolicy CS103KS.02

Prolotherapy and Platelet Rich Plasma Therapies (for Kansas Only)

This Kansas-only medical policy governs coverage determinations for prolotherapy and platelet-rich plasma (PRP) therapies provided to members covered by UnitedHealthcare in Kansas.

Policy Summary

PayerUnitedHealthcare

PolicyProlotherapy and Platelet Rich Plasma Therapies (for Kansas Only)

Policy CodePolicy CS103KS.02

Change TypeClinical evidence and references updated

Effective DateFeb 1, 2026

Next Review Date

Key ActionWhen requesting PRP or prolotherapy, document prior conservative therapies and clinical severity (e.g., Kellgren-Lawrence grade, baseline pain) to support medical necessity review.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence and References sections to reflect the most current information.

2therapies declared not medically necessary

Kansasstate applicability

6 monthscommon follow-up timepoint

Low/very lowoverall certainty of evidence

02/01/2026

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations and Evidence Summary

inv-01: Not Medically Necessary — prolotherapy and PRP

Covered when ALL of the following are met:

Primary stance: Prolotherapy and platelet-rich plasma are unproven and not medically necessary for any condition or indication.

Policy declares both therapies not medically necessary for any indication based on insufficient evidence.

inv-02: Knee osteoarthritis — evidence summary and typical trial inclusion

Evidence from randomized trials and systematic reviews is mixed; many KOA trials enrolled patients with defined radiographic severity and baseline pain thresholds and required prior conservative therapy.

Trial-based inclusion features: Kellgren-Lawrence grade 2–3 on radiograph AND baseline pain meeting trial thresholds (e.g., VAS ≥ 4) AND prior failure of conservative therapyKellgren-Lawrence grade 2–3; VAS ≥ 4

These reflect common enrollment criteria in KOA RCTs (Teymouri et al., Hsieh & Lee; Bennell et al.) and are trial-aligned but not an authorization guarantee.

Typical trial interventions and comparators: Interventions in trials included intra-articular PRP, dextrose prolotherapy, hyaluronic acid, and placebo (saline); comparators commonly were saline or HA with outcomes assessed at multiple timepoints up to 12 months.

Examples: Bennell et al. (placebo-controlled, n=288), Filardo meta-analysis, Hsieh & Lee co-injection trials.

Outcome expectations from evidence: Some trials and meta-analyses report modest pain/function improvement for PRP at 6–12 months, but a large placebo-controlled RCT found no 12-month benefit; heterogeneity in PRP formulation and study quality limit conclusions.

See Filardo et al. (meta-analysis) and Bennell et al. (2021 RCT).

inv-03: Lateral epicondylosis — RCT outcomes (large RCT, 24-month outcomes)

A large randomized trial and supporting reviews describe clinically meaningful, durable improvements for lateral epicondylosis with PRP and prolotherapy in some studies.

Key RCT findings: In an RCT of chronic lateral epicondylosis (n=231 enrolled, 202 completed) comparing PRP, prolotherapy, ESWT, and physiotherapy, PRP reduced DASH scores by ~31 points and prolotherapy by ~21 points at 24 months, with all groups exceeding the MCID (10 points).MCID = 10 points

Single large trial (Lhee et al.) showed durable 24-month benefit but had limitations including selection and attrition bias and subjective outcomes.

Supporting systematic review results: Systematic reviews and meta-analyses (e.g., Zhu et al., Masiello et al.) report that dextrose prolotherapy and PRP can reduce pain and improve function versus active controls at medium-term timepoints (commonly 12 weeks to 6 months); heterogeneity and study size limit certainty.

Pooled DPT results favored active controls at 12 weeks (Zhu et al.), but overall evidence graded low to very low for many comparisons.

inv-04: Evidence summaries and applicability

Study-level observations relevant to applicability and limitations of the evidence (not formal coverage rules):

Patient selection and prior therapy: Many trials enrolled patients with chronic symptoms (commonly >6 months) who were refractory to at least 3 months of nonoperative care; trials often excluded recent corticosteroid or botulinum injections and full tendon rupture.symptoms > 6 months; refractory to ≥3 months nonoperative care

Lhee et al. and several tendon/soft-tissue studies used these inclusion/exclusion approaches.

Outcome measures and objectivity: Most trials used patient-reported outcomes (e.g., DASH, VAS, WOMAC, KOOS); objective measures (e.g., grip strength, imaging) were less commonly reported, limiting structural interpretation of benefit.

Lhee et al. noted absence of objective measures; other studies similarly relied on PROMs.

Heterogeneity in preparations and dosing: PRP and prolotherapy protocols varied substantially across studies (concentration, leukocyte content, number/timing of injections, adjuncts), which affects applicability to routine practice.

inv-05: Evidence-based coverage considerations — summaries and implied coverage implications

Evidence synthesis and implications that inform coverage thinking (summary observations across indications):

Overall evidence quality: Across indications the overall certainty of evidence is frequently low to very low due to small sample sizes, heterogeneity in protocols, variable blinding, and short follow-up in many trials.

Multiple systematic reviews and technology assessments report low/very low certainty.

Indication-specific signals: There are some positive signals: TMJ and lateral elbow tendinopathy show consistent short- to mid-term symptom improvement in multiple RCTs/reviews; knee OA meta-analyses report modest benefit at 6–12 months but a large placebo-controlled RCT found no 12-month benefit.

See TMJ reviews (chunks 54–63), lateral epicondylosis RCT (chunk 36), KOA trials/meta-analyses (chunks 70–73).

Safety considerations: PRP and prolotherapy are generally well tolerated; however, leukocyte-rich PRP and some foot/ankle studies reported higher rates of transient postinjection pain and local adverse events (NNH ~13 in one review).

Some meta-analyses and systematic reviews document increased transient local pain and higher local AEs with LR-PRP.

inv-06: Evidence summary / coverage-relevant findings by indication

Indication-level evidence synthesis highlighting key trial and review findings relevant to coverage decisions:

Knee osteoarthritis (KOA): Systematic reviews/meta-analyses report modest improvements in pain/function with PRP at some timepoints (commonly 6–12 months) but findings are heterogeneous and evidence quality is low; a large placebo-controlled RCT (n=288) found no difference at 12 months.

Filardo et al. (meta-analysis) vs Bennell et al. (placebo RCT) illustrate contrasting results.

Lateral epicondylitis and tendinopathies: Some RCTs and meta-analyses (e.g., Zhu et al., Masiello et al.) report clinically meaningful pain and function improvements for lateral elbow tendinopathy and other tendinopathies in certain trials, but overall certainty is low and results vary by comparator and PRP/prolotherapy protocol.

Evidence mixed; individual large RCT (Lhee et al.) reported durable 24-month benefit for PRP and prolotherapy.

TMJ and oral/maxillofacial: Systematic reviews of hypertonic dextrose prolotherapy report reductions in TMJ pain and improvements in mouth opening up to 12 months in small RCTs, but studies are few and heterogeneous.

inv-07: Coverage considerations and clinical criteria — operational considerations for determinations

Practical coverage-related considerations and clinical criteria derived from the evidence base:

Conservative care prerequisite: Documented failure of an adequate trial of conservative therapy (e.g., structured physical therapy, activity modification, analgesics; commonly ≥3 months) prior to considering PRP or prolotherapy is expected based on trial populations.≥3 months conservative care

Many trials required refractory symptoms and compared PRP/prolotherapy to other noninvasive therapies.

Documentation aligned with trials: Clinical documentation should include diagnosis, duration of symptoms, prior therapies tried, objective radiographic grading where applicable (e.g., Kellgren-Lawrence for KOA), baseline PROMs (e.g., VAS, WOMAC, DASH), and details of proposed PRP/prolotherapy preparation and injection technique.Kellgren-Lawrence grade when applicable; baseline PROMs

Trial reporting commonly captured these elements (Bennell et al., Teymouri et al., Lhee et al.).

inv-08: Evidence-summary by indication — evidence quality and trial contexts

Evidence-quality notes and typical trial contexts summarized by indication to assist clinical reviewers:

Lateral epicondylitis: Randomized trials include comparisons of PRP, prolotherapy, corticosteroid, ESWT, and surgery; some trials show PRP/prolotherapy benefit at longer follow-up (≥6 months), but evidence heterogeneity and methodological limitations persist.

ECRI and Hayes reviews highlight mixed/inconclusive evidence for lateral epicondylitis despite some positive long-term signals.

Low back pain and spine indications: Small RCTs and network/meta-analyses show mixed results for intradiscal, facet, SIJ, and lumbopelvic PRP/prolotherapy; some small trials report short-term improvements but larger, higher-quality trials are lacking.

Zhang et al., Won et al., Tuakli-Wosornu trials illustrate heterogeneous findings and small sample sizes.

Wound care (DFU/VLU): Meta-analyses report increased complete healing for diabetic foot ulcers (moderate SOE) but heterogeneity in PRP preparation and study methods limit generalizability; evidence for venous and pressure ulcers is insufficient.

inv-09: Evidence summaries and society recommendations by indication

Extracted society guidance and assessment conclusions relevant to policy interpretation and coverage decisions:

AAOS (2022) states PRP may reduce pain and improve function for symptomatic knee OA based on low-quality evidence and recommends further research; AAOS guidance for glenohumeral OA and rotator cuff does not support routine PRP use due to insufficient evidence.low-quality evidence

AAOS guidance documents emphasize need for stratified analyses and standardization.

ACR and AAHKS: ACR 2019 strongly recommends against PRP for knee/hip OA and conditionally recommends against prolotherapy for knee/hip OA; AAHKS (2019) does not recommend biologics including PRP for advanced hip or knee arthritis.recommendation against

These societies discourage routine clinical use for OA in many contexts.

NICE and VA/DoD and ASIPP: NICE recommends PRP for KOA only with special arrangements (governance/consent/audit) and that PRP gel not be offered for diabetic foot outside trials; VA/DoD notes insufficient evidence to recommend for or against PRP in hip/knee OA; ASIPP classifies intradiscal PRP evidence as Level III (fair) and other spinal injections as Level IV (limited).

This policy declares that prolotherapy and platelet-rich plasma (PRP) are considered unproven and not medically necessary for any condition or indication, based on an overall insufficient evidence base to establish consistent clinical benefit.

Across systematic reviews and randomized trials, common methodological limitations include small sample sizes, short follow-up intervals, variable or inconsistent reporting of adverse events, and substantial heterogeneity in PRP and prolotherapy protocols (preparation, concentration, dosing, and administration). These limitations reduce confidence in pooled estimates and frequently result in low or very low certainty of evidence.

Many trials explicitly excluded patients who had received recent corticosteroid or botulinum toxin injections and those with complete tendon ruptures; these exclusion patterns are commonly used to define trial populations and inform clinical interpretation of results.

Studies and technology assessments consistently highlight that PRP preparations vary widely and are not standardized. Because of differences in platelet concentration, leukocyte content, activation, application methods, and dosing schedules, evidence for PRP frequently cannot be generalized across products or protocols and off-label or nonstandardized preparations lack supportive high-quality data.

Within the reviewed source excerpts there are no explicit procedural or population exclusions stated beyond the general determination that these therapies are unproven; instead, the document summarizes study-level exclusions and evidence limitations rather than imposing specific procedural exclusions in the cited chunks.

For rotator cuff and shoulder indications, the evidence is mixed: meta-analyses and systematic reviews report some short-term improvements with PRP in postoperative settings, but other high-quality assessments and RCTs show small or no clinically meaningful long-term benefit. Overall, available data do not support routine use of PRP for rotator cuff repair or shoulder tendinopathies.

Wound-care evidence shows some positive signals—notably for diabetic foot ulcers where systematic reviews report increased complete wound closure—but trials use heterogeneous PRP protocols and study quality varies. Because of inconsistency in methods and populations, routine use of PRP for wound healing is not supported without clear refractory disease, standardized preparation, or enrollment in research.

NICE guidance notes that PRP injections for knee osteoarthritis have limited-quality evidence and should be used only with special arrangements for clinical governance, consent, audit, or research. For diabetic foot problems, NICE recommends that autologous PRP gel should not be offered except as part of a clinical trial.

This Medical Policy is intended to assist interpretation of UnitedHealthcare standard benefit plans but does not replace applicable federal, state, or contractual benefit plan terms; where there is a conflict, federal, state, or contractual requirements govern coverage decisions.

Given the documented limitations and inconsistent findings, the policy explicitly states that prolotherapy and PRP are unproven and not medically necessary for any condition or indication.

Additional systematic reviews and RCTs in knee osteoarthritis report mixed outcomes: some meta-analyses favor PRP on certain pain and function measures at 6–12 months, while a large placebo-controlled trial (n = 288) found no difference versus saline at 12 months. Other placebo-controlled trials also show no superiority and sometimes higher transient pain with PRP.

Multiple reviewers and study authors call for further well-designed randomized controlled trials and standardized reporting, noting a risk of bias in many existing studies and concerns that subjective outcome measures and inconsistent blinding may inflate apparent benefits.

For mild-to-moderate knee osteoarthritis, evidence from randomized trials is not consistently supportive of PRP: a large, well-conducted RCT found no clinically important benefit at 12 months, and meta-analyses emphasize low-quality and heterogeneous data, so PRP for this population is not supported by consistent high-quality evidence.

Across indications, authors repeatedly recommend larger, rigorously designed RCTs with standardized PRP/prolotherapy protocols and objective outcome measures to resolve uncertainty about efficacy and optimal patient selection.

For tendinopathies, systematic reviews and pooled analyses generally find insufficient, low-certainty evidence to support routine PRP use. Although some studies and an individual large RCT in lateral epicondylosis reported clinically meaningful improvements, the broader literature is inconsistent and does not justify routine adoption.

In one randomized comparison of PRP versus arthroscopic lateral release for chronic lateral epicondylitis, both treatments improved outcomes but arthroscopic release produced better long-term results; this finding suggests that PRP may be inferior to established surgical options for some patients.

The 2019 American College of Rheumatology/Arthritis Foundation guideline strongly recommends against PRP for knee and hip osteoarthritis and conditionally recommends against prolotherapy for these indications.

Applicable and Related Codes

Applicable Codes (example CPT)CPT

0232T

Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed.

Applicable / Related HCPCSHCPCS

G0460	Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers (includes, as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment)
G0465	Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication, (includes as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).
M0076	Prolotherapy
P9020	Platelet-rich plasma, each unit

Coding referencedmixed

not specified

No specific CPT/HCPCS/ICD-10 codes listed in these chunks

No procedure/billing codes listed in this sectionmixed

No codes listed

Radiographic grade for inclusion in trials

Radiographic inclusion criteriaKellgren-Lawrence grade 2–3 (mild to moderate knee osteoarthritis as used in multiple RCTs)

ContextThis radiographic grading reflects common trial enrollment criteria rather than an explicit coverage requirement in the policy

Typical use in trialsUsed to define disease severity for patient selection in KOA studies comparing DPT/PRP with placebo or other injectables

Baseline pain threshold used in trials

Baseline pain thresholdVisual Analog Scale (VAS) ≥ 4 as an enrollment requirement in many KOA RCTs

Authorization, Documentation, and Clinical Practice Guidance

Prior Authorization

Prior authorization — reference to listed code (include 0232T)

Prior authorization: include the applicable procedure codes when requesting review. The policy lists CPT 0232T (Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation), HCPCS G0460/G0465 (autologous PRP for nondiabetic/diabetic chronic wounds when using an FDA‑cleared device), M0076 (Prolotherapy), P9020 (Platelet-rich plasma, each unit), and P9020-related descriptors. Ensure claims and PA requests reference these codes and any plan-specific code mapping.

Include CPT 0232T when applicable
Include HCPCS G0460/G0465 for wound-related PRP per device/indication
Reference M0076 and P9020 where used

Prior Authorization

Prior authorization: radiographic grade and baseline symptoms

When requesting prior authorization for knee osteoarthritis (KOA) interventions such as PRP, provide objective radiographic grading (e.g., Kellgren‑Lawrence grade) and baseline symptom measures (eg, VAS, WOMAC, KOOS). Trials frequently enrolled KL grade 2–3 and required baseline pain thresholds (eg, VAS ≥4) or symptom duration criteria.

Clinical Background and Definitions

Prolotherapy is described as an injection-based regenerative approach using agents such as dextrose intended to stimulate a local inflammatory response to promote tissue repair; the method and agents vary across studies and are a source of heterogeneity in the evidence base.

Prolotherapy — definition and typical agents

DefinitionProlotherapy: injection of any substance (e.g., dextrose, saline, sarapin, procaine, or lidocaine) intended to stimulate healing and promote growth of normal ligament, tendon, or joint tissue by provoking a mild inflammatory response

Typical agentsHypertonic dextrose solutions (various concentrations), saline, sarapin, procaine, lidocaine; newer formulas may include PRP or autologous stem cell sources

Therapeutic intentTo induce local inflammation and tissue proliferation leading to gradual tissue strengthening over repeated treatments

PRP — definition (autologous platelet concentrate) overview

Policy Version and Changes

2026-02-01Policy version effectiveLatest

Policy version CS103KS.02 became effective; Clinical Evidence and References sections updated and prior version CS103KS.01 archived.

Policy Summary

PayerUnitedHealthcare

PolicyProlotherapy and Platelet Rich Plasma Therapies (for Kansas Only)

Policy CodePolicy CS103KS.02

Change TypeClinical evidence and references updated

Effective DateFeb 1, 2026

Next Review Date

Key ActionWhen requesting PRP or prolotherapy, document prior conservative therapies and clinical severity (e.g., Kellgren-Lawrence grade, baseline pain) to support medical necessity review.

SourceLink

On This Page

Multiple systematic reviews and RCTs document lack of standardization.

Bahgat et al., Saramantos, and Sit et al. reviews summarized positive but limited evidence.

Wounds and diabetic foot ulcers: Meta-analysis (Qu et al.) found PRP increases complete healing for diabetic foot ulcers (moderate SOE) but evidence for venous and pressure ulcers is insufficient; heterogeneity and protocol issues limit generalizability.moderate/low SOE for DFUs

Qu et al. reported RR 1.20 for DFU healing.

Surgical augmentation and other orthopedics: PRP augmentation for surgical repairs (ACL, meniscus, rotator cuff) yields inconsistent and generally low-quality evidence with limited proven long-term benefit; short-term symptom improvements reported in some contexts but not consistently for structural outcomes.

Several systematic reviews and Hayes/ECRI assessments report limited or no proven benefit.

Prior authorization considerations: Given heterogeneous evidence—particularly for KOA where large RCTs show no benefit—prior authorization may be appropriate to ensure appropriate patient selection, documentation of prior conservative care, and specification of PRP/prolotherapy preparation and dosing.

Policy analyses recommend PA when evidence is low/heterogeneous.

Informed consent and safety documentation: Obtain and document informed consent discussing variable efficacy, potential for increased transient postinjection pain (noted in foot/ankle trials), and paucity of long-term outcome data; record PRP leukocyte status if available due to differences in local AE rates.

Systematic reviews note higher transient pain and more local AEs with LR-PRP in some analyses.

moderate SOE for DFU; insufficient for VLU/PU

Qu et al. and Martinez-Zapata analyses described these findings.

restricted use/research only / insufficient evidence

Society guidance supports cautious or research-limited use and underscores need for governance.

Defines minimum symptom burden for trial eligibility and aligns with documented trial inclusion criteria

Documentation notedTrials commonly capture baseline VAS scores alongside radiographic grading to characterize participants

Report Kellgren‑Lawrence grade (document imaging date)
Provide baseline pain scores (VAS/NPRS) and functional scores (WOMAC/KOOS)
State symptom duration and prior response to conservative care

Prior Authorization

Clinical prerequisites commonly used as authorization justification

Clinical prerequisites commonly used to justify authorization requests include documentation of refractory symptoms after adequate conservative therapy, diagnostic confirmation of the target condition, and specific inclusion criteria aligning with trial populations (eg, symptom duration, baseline pain/function thresholds).

Document prior conservative treatments (physical therapy, NSAIDs, weight loss, bracing) and dates/outcomes
Include diagnostic confirmation (clinical exam, imaging, ultrasound/MRI where relevant)
Provide symptom duration and severity consistent with cited trials

Prior Authorization

Prior authorization advisable for PRP in KOA

Prior authorization is advisable for intra‑articular PRP for KOA because evidence is mixed and heterogeneous, including at least one large, well‑conducted RCT showing no clinically meaningful benefit. PA allows review of appropriateness (KL grade, prior conservative care, symptom severity) and documentation of specific PRP protocol.

Provide KL grade and prior conservative care documentation
Describe PRP preparation (leukocyte‑poor vs leukocyte‑rich), number and timing of injections
Note large RCTs with negative findings to support careful review

Prior Authorization

Prior authorization recommended for PRP

Prior authorization is recommended for PRP procedures in conditions with heterogeneous evidence (eg, tendinopathies, foot/ankle, wounds). When requesting PA, include explicit documentation of prior conservative care, rationale for PRP, and procedural details (guidance modality, number/timing of injections).

List prior conservative therapies tried and dates
Describe image guidance (eg, ultrasound) and injection protocol
If for wound care, specify device used (FDA‑cleared device for diabetic wounds when applicable)

Prior Authorization

Prior authorization recommended for PRP procedures

Prior authorization recommended specifically for PRP procedures: supply procedure notes, PRP composition (if available), platelet/WBC counts, harvesting/preparation method, and number of units (P9020) to support clinical review.

Procedure note including image guidance and laterality
PRP composition: platelet count, leukocyte status, volume per injection
Number of injections and treatment schedule

Note

Prior authorization — not specified in provided text (confirm plan rules)

The policy text does not specify a single universal administrative prior authorization rule for all members and plans. Benefit coverage and PA requirements may vary by federal, state, or contractual plan terms; confirm plan‑specific PA processes.

If no PA guidance exists in plan documents, follow the payer’s standard PA process
Verify state or contract‑level mandates that may alter PA requirements

Note

Use of InterQual® and policy criteria

UnitedHealthcare uses InterQual® for primary medical/surgical criteria. When applicable InterQual® criteria exist, those criteria may be applied in addition to or instead of medical‑policy criteria during authorization review.

Check InterQual® applicability for the requested procedure or condition
If InterQual® lacks applicable criteria, UnitedHealthcare may apply approved medical policies

Denial Risk

Evidence limitations that may affect coverage decisions

Evidence limitations that may affect coverage decisions include small sample sizes, heterogeneity of PRP preparations and protocols, inconsistent outcome measures and follow‑up durations, and risk of bias in many trials. Such limitations can justify denials or requests for additional documentation.

Highlight variation in PRP preparation and lack of standardization
Note short follow‑up in many studies and inconsistent reporting of adverse events
Large, negative RCTs (eg, Bennell et al.) may prompt additional scrutiny

Note

No explicit administrative authorization specified in provided text

No explicit administrative authorization triggers (eg, automatic denial criteria) are specified in the policy text; operational PA triggers should follow plan contract language and InterQual® when applicable.

Adjudication follows benefit plan terms and InterQual® where used
Provide full clinical documentation to avoid delays

Note

Not applicable information in this evidence (plan exceptions govern)

Not applicable information: this policy treats prolotherapy and PRP as unproven/not medically necessary for general coverage per the Coverage Rationale; however plan‑specific exceptions or authorizations may exist based on contract terms.

Refer to the member’s federal/state/contractual benefit for applicability
Document any compassionate‑use or trial participation separately

Denial Risk

Safety signal for foot/ankle PRP — higher post‑injection pain reported

Safety signal for foot and ankle PRP: higher rates of transient post‑injection pain and an overall higher complication rate were reported in systematic reviews for foot/ankle conditions (eg, Achilles, plantar fasciitis). PA reviewers should consider these safety signals when evaluating appropriateness.

Report prior adverse reactions to injections
Document rationale for PRP vs alternative conservative treatments given higher post‑injection pain risk

Denial Risk

Heterogeneous and low‑quality evidence may prompt review or limitation

Heterogeneous and low‑quality evidence for many indications (tendinopathies, KOA, wounds, spine) supports using PA to ensure appropriate patient selection and documentation or to limit routine coverage outside trials.

Require documentation of failed conservative care and alignment with trial‑like inclusion criteria
Consider coverage only within clinical trials or with special governance when evidence is limited (NICE guidance)

Documentation Required

Off‑label agent use and device regulation — document device/indication

Off‑label agent use and device regulation: PRP and prolotherapy are procedural uses of approved agents (eg, dextrose, lidocaine) and are not FDA‑approved indications; devices used to prepare PRP may have FDA clearance for specific wound indications. PA should note any off‑label use and whether an FDA‑cleared device was used for wound‑related PRP.

If treating diabetic foot ulcers, specify if an FDA‑cleared device was used (G0465)
Document off‑label use and obtain informed consent when relevant

Documentation Required

Claims coding and documentation

Claims coding and documentation: include the CPT/HCPCS codes (see list above), diagnosis codes supporting the indication, operative/procedure notes, and any laboratory or composition data for PRP. Use plan‑specific billing guidance when submitting claims.

Attach procedure note (guidance, laterality, number of injections)
Include diagnosis codes and supporting imaging reports
Supply PRP composition data if available (platelet/WBC counts)

Documentation Required

Typical clinical documentation captured in trials

Typical clinical documentation captured in trials that supports prior authorization: Kellgren‑Lawrence grade for KOA, baseline VAS/NPRS, WOMAC/KOOS/DASH/IKDC scores, symptom duration, prior conservative therapies, and imaging (MRI/ultrasound) findings. Include these items in the PA request to mirror trial inclusion and aid review.

KL grade and imaging date
Baseline pain and functional scores (WOMAC, KOOS, DASH, VAS)
Documentation of prior conservative care and its duration

Documentation Required

Clinical trial–aligned documentation

Clinical trial–aligned documentation: trials commonly reported outcome measures (pain scores, functional scales), imaging endpoints (eg, MRI cartilage volume in KOA), and procedural details (ultrasound guidance, number/timing of injections). Provide these where available to facilitate clinical review.

Provide baseline and follow‑up outcome scores (specify timepoints)
Include MRI or other imaging reports if structure outcomes are claimed
Report number/timing of injections and any concurrent therapies

Documentation Required

Studies frequently lack standardized PRP details — provide composition if available

Studies frequently lack standardized PRP reporting: many trials do not report platelet or leukocyte counts, preparation methods, or injection volumes. When available, include platelet/WBC counts and a description of the preparation technique in PA requests to improve transparency.

Report platelet concentration and leukocyte status (LP vs LR)
Describe centrifugation/kit/device used and volumes injected

Note

Reference benefit plan terms (plan contract governs)

Reference benefit plan terms: coverage decisions must follow the member’s federal, state, or contractual plan requirements. In the event of conflict between this policy and plan language, the plan contract governs.

Verify state/contractual mandates that may require coverage
Document any plan exceptions or trial enrollment that may alter coverage

Prior Authorization

Expectation to trial conservative care before PRP

Expectation to trial conservative care: trials generally required that participants had inadequate response to conventional therapies (eg, physical therapy, NSAIDs, activity modification). Authorization requests should document prior conservative management and outcomes.

Document specific conservative measures tried with dates and response
If corticosteroid injections were used, document timing relative to proposed PRP

Note

Studies commonly included prior or concurrent conservative therapies

Studies commonly included prior or concurrent conservative therapies; many trials enrolled patients after failure of noninvasive measures or permitted continuation of structured exercise programs. PA requests should clarify whether PRP is additive or used after failed conservative options.

State whether PRP is adjunctive or second‑line after failed therapy
Provide rehabilitation/physical therapy records when relevant

Prior Authorization

Conservative therapy first — document failed conservative measures

Conservative therapy first: multiple trials required documentation of failed conservative measures (often >=3 months). Denials are more likely when conservative care is not adequately documented.

Document duration (eg, ≥3 months) and types of conservative therapy attempted
Include clinician notes summarizing lack of improvement with conservative care

Documentation Required

Conservative therapies prior to PRP — document steroid and other prior injections

Conservative therapies prior to PRP: corticosteroid injections often provide short‑term relief and were common comparators in trials; document prior steroid use and timing as it may affect eligibility for PRP and PA review.

Note dates of prior corticosteroid injections and clinical response
Explain rationale for choosing PRP after steroid or other interventions

Note

Combination therapy considerations — document concurrent therapies and plan

Combination therapy considerations: professional guidance (eg, ASIPP) and some trials permit PRP/regenerative therapies to be combined with structured exercise, physical therapy, or conventional medical therapy. If PRP will be combined with other modalities, document the coordinated treatment plan.

Describe concurrent or planned rehabilitation, medications, or procedures
Provide timeline and responsibility for follow‑up and outcome assessment

Platelet-rich plasma (PRP): an autologous blood preparation concentrated for platelets and platelet-derived growth factors and cytokines used as an injectable biologic

SourcePrepared from the patient’s own blood (autologous); platelet concentration and leukocyte content vary by preparation

Clinical contextEvaluated across musculoskeletal indications (e.g., knee osteoarthritis, tendinopathies, surgical augmentation) with heterogeneous protocols

DPT (dextrose prolotherapy) — definition and administration routes

DPT definitionDextrose prolotherapy (DPT/HDPT): injection therapy using hypertonic dextrose solutions administered intra‑articularly or peri‑articularly to provoke a local inflammatory response and stimulate tissue repair

Concentrations and routesStudies have used a range of dextrose concentrations (examples include 5%, 15%, 25%, 50% depending on protocol) administered intra‑articularly or peri‑articularly; TMJ and joint injections commonly reported

Adjunct techniquesDPT is sometimes combined with local anesthetic (e.g., lidocaine) or dry needling in study protocols

PRP (platelet-rich plasma) — definition (trial-context notes)

Trial-context definitionPRP in trial settings is an autologous platelet concentrate injected intra‑articularly or into soft tissues to deliver growth factors intended to enhance healing; preparation and dosing vary across studies

Components reportedStudies report platelet concentration, leukocyte content (leukocyte‑rich vs leukocyte‑poor), volume, activation method and number/timing of injections — though reporting is inconsistent

Comparator interventionsIn RCTs PRP has been compared with placebo (saline), hyaluronic acid, corticosteroid, prolotherapy, and other injectables

PRP (platelet-rich plasma) — clinical intent and common target tissues

Clinical intentPRP is used to promote tissue healing and reduce pain in tendon and peri‑tendinous disorders (e.g., lateral epicondylitis, rotator cuff tendinopathy) and intra‑articularly for joint conditions

Common target tissuesTendons, peri‑tendinous tissues, intra‑articular joint spaces (knee, hip), and soft‑tissue injury sites

Typical goalsImprove pain, function, and possibly structural healing when used as an adjunct to conservative or surgical treatments

Platelet-rich plasma (PRP) — heterogeneity in preparations noted

Heterogeneity statementPRP preparations are heterogeneous and lack standardization across studies (variation in platelet concentration, leukocyte content, activation, volume, application method, and number/timing of injections)

ImplicationThis variability limits comparability of RCTs and meta‑analyses and contributes to uncertainty about efficacy and optimal protocols

Reporting gapsMany studies do not consistently report key PRP composition metrics (platelet/WBC counts, growth factor assays) or standardized application methods

Hypertonic dextrose prolotherapy (DPT/HDPT) — definition and combination approaches

DefinitionHypertonic dextrose prolotherapy (DPT/HDPT): injection of concentrated dextrose solutions into intra‑ or peri‑articular tissues to elicit a reparative inflammatory response

Combination approachesOften combined in studies with local anesthetic (e.g., lidocaine), image guidance, or dry needling; dosing and frequency vary by protocol

Indications studiedEvaluated for TMJ internal derangement, tendinopathies, osteoarthritis, and ligament injuries in small RCTs and case series

PRP — repeated definition entries across document

Repeated definitionPRP: an autologous platelet concentrate delivering growth factors and cytokines used intra‑articularly or into soft tissue to potentially enhance healing; documented repeatedly throughout the policy

Usage noteApplied across knee OA, tendinopathies, surgical augmentation, and wound care studies with varied outcomes

Preparation variabilityPreparations described variably as leukocyte‑rich or leukocyte‑poor and differ in concentration and activation methods

LR-PRP — leukocyte-rich PRP variant and adverse event association

LR‑PRP variantLeukocyte‑rich PRP (LR‑PRP) is a commonly reported variant characterized by higher white blood cell content

Adverse event associationSome analyses report more local adverse events and transient increased post‑injection pain with LR‑PRP compared with leukocyte‑poor formulations

Clinical relevanceChoice of leukocyte content may influence tolerability and local inflammatory response; evidence remains inconclusive

PRP heterogeneity — variation in preparation and reporting across studies

Variation in protocolsPRP studies differ in platelet concentration, leukocyte content, activation, injection volume, number and timing of injections, and application method

Effect on evidenceHeterogeneous protocols impede pooling of results and limit conclusions about optimal PRP technique or dose–response

Recommendation in literatureAuthors frequently call for standardized reporting of PRP composition and treatment protocols in future trials

PRP heterogeneity — additional notes about protocols and sessions

Protocol and session variabilityPRP trials report single versus multiple injections (20 trials single, 13 multiple in one review), with intervals ranging from weekly to monthly

Incomplete reportingMany trials omit standardized measures of platelet/WBC counts or activation status, limiting reproducibility

Clinical trial implicationsNumber and timing of sessions vary by indication; such differences are noted as a key source of heterogeneity in systematic reviews

Autologous PRP/PRF — definitions for related platelet-derived products

Autologous PRP/PRF definitionsAutologous PRP and platelet‑rich fibrin (PRF) are patient‑derived platelet concentrates prepared for injection or topical use to promote tissue healing and regeneration

Product formsPRP typically used as injectable liquid concentrates; PRF is a fibrin matrix variant used for soft‑tissue regeneration and topical wound applications

Evidence contextBoth PRP and PRF have been evaluated in wound healing and soft‑tissue regeneration studies with mixed results and varied study designs

Platelet-rich plasma (PRP) — general usage across knee and soft-tissue indications

General usagePRP has been applied across knee osteoarthritis, tendinopathies (lateral epicondylitis, plantar fasciitis, Achilles), surgical augmentation, and wound care in clinical studies

Indication variabilityEffect sizes and certainty of benefit vary substantially by indication; some meta‑analyses suggest short‑term improvements while others find no difference

Clinical takeawayUse and outcomes are indication‑specific and influenced by preparation heterogeneity and study quality

Prolotherapy (hypertonic dextrose) — definition and study contexts

Definition summaryProlotherapy (hypertonic dextrose): injection therapy using concentrated dextrose (DPT/HDPT) administered intra‑ or peri‑articularly intended to stimulate tissue repair and reduce pain

Study contextsEvaluated in RCTs and systematic reviews for TMJ dysfunction, osteoarthritis, tendinopathies, and ligament injuries with variable concentrations and follow‑up durations

Reported outcomesSome trials report short‑term to mid‑term improvements in pain and function (e.g., TMJ, lateral epicondylitis), but heterogeneity and small sample sizes limit definitive conclusions